Related Experiment Video
Updated: Jun 10, 2026

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
Published on: January 19, 2015
Dual concentration-dependent effect of ascorbic acid on PAP(248-286) amyloid formation and SEVI-mediated HIV
Satabdee Mohapatra1, Guru Krishna Kumar Viswanathan1, Lukas Wettstein2
1Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University Tel Aviv 69978 Israel dsegal@post.tau.ac.il.
Abstract:
Human semen contains various amyloidogenic peptides derived from Prostatic Acid Phosphatase (PAP) and Semenogelin proteins that are capable of enhancing HIV-1 infection when assembled into fibrils. The best characterized among them is a 39 amino acid peptide PAP(248-286), which forms amyloid fibrils termed SEVI (semen-derived enhancer of viral infection) that increase the infectivity of HIV-1 by orders of magnitude. Inhibiting amyloid formation by PAP(248-286) may mitigate the sexual transmission of HIV-1. Several vitamins have been shown to reduce the aggregation of amyloids such as Aβ, α-Synuclein, and Tau, which are associated with neurodegenerative diseases. Since ascorbic acid (AA, vitamin C) is the most abundant vitamin in semen with average concentrations of 0.4 mM, we here examined how AA affects PAP(248-286) aggregation in vitro. Using ThT binding assays, transmission electron microscopy, and circular dichroism spectroscopy, a dual and concentration-dependent behavior of AA in modulating PAP(248-286) fibril formation was observed. We found that low molar ratios of AA:PAP(248-286) promoted whereas high molar ratios inhibited PAP(248-286) fibril formation. Accordingly, PAP(248-286) aggregated in the presence of low amounts of AA enhanced HIV-1 infection, whereas excess amounts of AA during aggregation reduced the infectivity enhancing effect in cell culture. Collectively, this work provides a biophysical insight into the effect of AA, an important seminal component, on SEVI fibrillation which might impact amyloid formation kinetics, thereby modulating the biological activity of semen amyloids.
Insights
Ascorbic acid (vitamin C) in semen has a dual effect on semen-derived enhancer of viral infection (SEVI) amyloid formation. Low concentrations promote SEVI aggregation and HIV-1 enhancement, while high concentrations inhibit it.
Area of Science:
- Biophysics
- Molecular Biology
- Virology
Background:
- Human semen contains amyloidogenic peptides, such as PAP(248-286), that form SEVI fibrils.
- SEVI fibrils significantly enhance HIV-1 infectivity, contributing to sexual transmission.
- Ascorbic acid (vitamin C) is abundant in semen and known to affect amyloid aggregation.
Purpose of the Study:
- To investigate the effect of ascorbic acid (AA) on the aggregation of PAP(248-286) in vitro.
- To understand how AA influences the formation of SEVI fibrils and their impact on HIV-1 infectivity.
Main Methods:
- Thioflavin T (ThT) binding assays to monitor fibril formation.
- Transmission electron microscopy (TEM) to visualize fibril structure.
- Circular dichroism (CD) spectroscopy to analyze secondary structure changes.
- Cell culture assays to assess HIV-1 infectivity.
Main Results:
- Ascorbic acid exhibited a concentration-dependent dual effect on PAP(248-286) aggregation.
- Low AA:PAP(248-286) molar ratios promoted fibril formation.
- High AA:PAP(248-286) molar ratios inhibited fibril formation.
- Low AA enhanced SEVI's ability to increase HIV-1 infectivity, while high AA reduced this effect.
Conclusions:
- Ascorbic acid modulates SEVI fibrillation in a concentration-dependent manner.
- The findings provide biophysical insights into how a seminal component affects amyloid formation and HIV-1 infectivity.
- Understanding this interaction may inform strategies to mitigate sexual HIV-1 transmission.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Inhibitors of Virion Maturation and Assembly

